This manual attempts to provide simple, adequate and evidence-based information to health care professionals in primary health care especially in low- and middle-income countries to be able to provide pharmacological treatment to persons with mental disorders. The manual contains basic principles of prescribing followed by chapters on medicines used in psychotic disorders; depressive disorders; bipolar disorders; generalized anxiety and sleep disorders; obsessive compulsive disorders and panic attacks; and alcohol and opioid dependence. The annexes provide information on evidence retrieval, assessment and synthesis and the peer view process.
Brand new 2015 edition, with an expanded section on "off-label" and experimental options, along with a fascinating explanation of the current research into the next generation of drugs to treat mood & anxiety-spectrum disorders Are you confused about which antidepressant is right for you? Would you like to learn all the important information on all of the antidepressants currently available? Do you suffer from - - Major depression (including treatment-resistant depression and dysthymia) - Generalized anxiety disorder - Panic disorder - Phobic disorder - Obsessive compulsive disorder (OCD) ...or any mood disorder which is one the depressive or anxious spectrum? There are huge differences even between just SSRIs, let alone the huge number of alternatives you have probably never heard of. Unfortunately, doctors tend to be incredibly busy, and sometimes they just don't have the time to finely calibrate your treatment. This means that very often, you will just be given the drug your doctor has the most experience in. This may or may not be the right tool for the job. Quite often we see the example of two patients visiting the same doctor - one patient anxious and one patient lethargic and depressed. Yet both emerge from the doctor's office with a prescription for the same SSRI. Depression and anxiety are incredibly varied conditions. Some people are "anxious depressed" whereas others can be more "low energy depressed." Or if we look specifically at anxiety disorders, the right drug (and dosage) for someone with panic disorder and for someone with OCD is dramatically different. Each condition needs a slightly different pharmacological approach. This comprehensive, encyclopedic guide by Benjamin Kramer (author of Brain Renovation), provides detailed information on every common antidepressant and anxiolytic (anti-anxiety medication) such as - - SSRIs (Selective serotonin re-uptake inhibitors - such as Zoloft, Paxil, Prozac & Lexapro) - SNRIs (Serotonin & Norepinephrine re-uptake inhibitors - such as Effexor & Cymbalta) - Atypical antidepressants (such as Remeron, Buspar & Wellbutrin) - TCAs (Tricyclic antidepressants - such as Endep & Anafranil) - Benzodiazepines (such as Xanax, Ativan & Klonopin) - "Off-label" and experimental options including stimulants (amphetamine, methylphenidate), Lyrica, tramadol memantine and ketamine - Upcoming drugs due to become available soon Learn about how the slight differences between each drug can be the difference between success and failure. There is no such thing as the 'best' antidepressant - it depends on the individual and the nature of the illness. Are you anxious and depressed? Are you unmotivated with a lack of energy? Can't sleep? In pain? All these factors should influence your doctor's (and your own) choice as to the best option for you. Kramer also addresses the most common questions people have when starting an antidepressant or looking for one which works, such as - - Which medications won't make me put on weight? - Which medications will kill my libido? What adjunct options do I have for restoring libido? - How long will the medication take to start working? So before you visit your physician, get as much information as possible so you can participate in the decision-making process aimed at deciding on the best treatment. To this end, Kramer has also included brand new "layman's" explanations of the most common questions around exactly how each drug works, including - - How does an SSRI (selective serotonin reuptake inhibitor) work? - How does a tricyclic work? - How does a MAOI (monoamine oxidase inhibitor) work? - What is the different between an agonist and an antagonist? - How can I tell which drug is the most potent?
World-renowned coverage of today's pharmacology at your fingertips - Keeps you up-to-date with new information in this fast-changing field, including significantly revised coverage of CNS drugs, cognitive enhancers, anti-infectives, biologicals/biopharmaceuticals, lifestyle drugs, and more. - Includes access to unique features, including more than 100 brand new chapter-specific multiple-choice questions and 6 new cases for immediate self-assessment. - Features a color-coded layout for faster navigation and cross-referencing. - Clarifies complex concepts with Key Points boxes, Clinical Uses boxes and full-color illustrations throughout.
"_This widely used book is packed with indispensable tools for treating the most common clinical problems encountered in outpatient mental health practice. Chapters provide basic information on depression and the six major anxiety disorders; step-by-stepinstructions for evidence-based assessment and intervention; illustrative case examples; and practical guidance for writing reports and dealing with third-party payers. In a convenient large-size format, the book features 125 reproducible client handouts, homework sheets, and therapist forms for assessment and record keeping. The included CD-ROM enables clinicians to rapidly generate individualized treatment plans, print extra copies of the forms, and find information on frequently prescribed medications._New to This Edition*The latest research on each disorder and its treatment.*Innovative techniques that draw on cognitive, behavioral, mindfulness, and acceptance-based approaches.*Two chapters offering expanded descriptions of basic behavioral and cognitive techniques.*47 of the 125 reproducibles are entirely new. __"--Provided by publisher.
Disorders of anxiety and substance use are, for some reason, rarely treated in an integrated fashion by professionals. This timely volume addresses this glaring omission with dispatches from the frontlines of research and treatment. Thirty-four international experts offer findings, theories, and intervention strategies for this common form of dual disorder, across a range of substances and of anxiety disorders, to give the reader comprehensive knowledge in a practical format.
Fluoxetine, best known by the trade name Prozac®, unlike other psychotropic drugs whose effects were serendipitously stumbled upon, was the first developed for a precise mechanism of action, that is, the ability to selectively inhibit serotonin reuptake, based upon the theory that increasing the availability of serotonin would treat major depression. Once approved by the FDA in 1987, fluoxetine quickly became the most prescribed psychotropic drug worldwide and its success in improving mood disorders has triggered the development of a large number of congener molecules, commonly known as SSRIs after their purported mechanism of action. However, a quarter of a century after its development, the idea that fluoxetine asserts its positive behavioral effect through inhibition of serotonergic reuptake is not firmly established. This book reviews several preclinical and clinical reports suggesting that the pharmacological effects of fluoxetine may be mediated by means other than the regulation of serotonin, including the regulation of gene expression, modifying epigenetic mechanisms as well as modifying microRNAs. One of the most prominent mechanisms for the therapeutic relevance of fluoxetine relates to influencing neuroplasticity by enhancing neurotropic factors, including BDNF signaling and altering adult neurogenesis. The ability of fluoxetine to rapidly increase neurosteroid levels accounts for the fast anxiolytic effects of this drug. Fluoxetine action at sigma-1 receptor or modulating glutamatergic neurotransmission as well as the combination of fluoxetine with other psychotropic drugs is discussed in relation to its therapeutic effects. While fluoxetine was primarily prescribed as an antidepressant, this drug currently represents a treatment of choice for a broad spectrum of psychiatric disorders, including post-traumatic stress disorder and a range of anxiety disorders. This drug even possesses analgesic actions and is a valuable therapy for stroke. This book also highlights emerging evidence on the gender-specific effects of fluoxetine, its potential adverse features, including its addiction liability in combination with psychostimulants, and the impact of perinatal fluoxetine exposure.
Recently, there has been a growing awareness of the multiple interrelationships between depression and various physical diseases. Patients with psychiatric problems, particularly depression, may be more susceptible to cardiovascular disorders. Depression and Heart Disease synthesizes current evidence, including some previously unpublished data, in a concise, easy-to-read format. The authors succinctly describe the epidemiology, pathogenesis (including cytokines and genetics), and risk factors of the comorbidity between depression and heart disease. The book also reviews the best pharmacological and psychotherapeutic approaches for people with this comorbidity.
